checkAd

     165  0 Kommentare Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb Application - Seite 4

    Investor Contact
    John Mullaly
    LifeSci Advisors, LLC
    617-429-3548
    jmullaly@lifesciadvisors.com


    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    Seite 4 von 4

    Verfasst von globenewswire
    Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb Application - Seite 4 Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. …